Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Morphotek, a subsidiary of Eisai, has signed a cooperative research and development agreement with the National Institute of Allergy and Infectious Diseases, a component of the National Institutes of Health, for the development of human monoclonal antibodies for the treatment of infectious disease.
Subscribe to our email newsletter
Morphotek will apply its Libradoma technology to isolate and initially characterize candidate antibodies and the National Institute of Allergy and Infectious Diseases (NIAID) will further characterize the antibodies to identify candidates potentially useful in treating and preventing certain infectious diseases.
Morphotek’s Libradoma technology is said to generate libraries of hybridomas that can be rapidly screened to identify monoclonal antibodies against disease-associated antigens.
Nicholas Nicolaides, president and CEO of Morphotek, said: “We remain committed to advancing candidates for clinical development in this therapeutic area, which if promising, may one day become available to patients with infectious disease.”